Novo Nordisk’s market capitalisation ($410bn) is now larger than Denmark’s annual GDP of last year ($400bn), raising concerns that the country’s fortunes have become too closely tied to a single company, as it had happened with Nokia and Finland. Diabetes treatment ‘Ozempic‘, and anti-obesity medication ‘Wegovy‘, made Novo Nordisk Europe’s most valuable company, stopping Denmark from falling into recession.
Read more on FT.com
